Monitoring of human papillomavirus vaccination.
(2011) In Clinical and Experimental Immunology Dec. p.17-25- Abstract
- Persistent infection with oncogenic human papillomavirus (HPV) is a necessary causal factor in the development of cervical cancer. Moreover, HPV, predominately type 16 and to a lesser degree type 18, is linked causally to varying proportions of other anogenital cancers (vulva, vagina, penis, anus) as well as cancers elsewhere in the body (oropharynx, larynx, conjunctiva). HPV types 6 and 11 cause most of genital warts and recurrent respiratory papillomatosis. Effective prophylactic vaccines have been developed. In this review, we address briefly the immunological aspects of HPV infection and the results of HPV vaccination trials. Internationally standardized monitoring and evaluation of prophylactic HPV vaccination programmes will be... (More)
- Persistent infection with oncogenic human papillomavirus (HPV) is a necessary causal factor in the development of cervical cancer. Moreover, HPV, predominately type 16 and to a lesser degree type 18, is linked causally to varying proportions of other anogenital cancers (vulva, vagina, penis, anus) as well as cancers elsewhere in the body (oropharynx, larynx, conjunctiva). HPV types 6 and 11 cause most of genital warts and recurrent respiratory papillomatosis. Effective prophylactic vaccines have been developed. In this review, we address briefly the immunological aspects of HPV infection and the results of HPV vaccination trials. Internationally standardized monitoring and evaluation of prophylactic HPV vaccination programmes will be essential for arriving at the most cost-effective strategies for cancer control. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1732139
- author
- Dillner, Joakim LU ; Arbyn, M ; Unger, E and Dillner, Lena LU
- organization
- publishing date
- 2011
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Clinical and Experimental Immunology
- volume
- Dec
- pages
- 17 - 25
- publisher
- British Society for Immunology
- external identifiers
-
- wos:000284851800003
- pmid:21062269
- scopus:78649721287
- pmid:21062269
- ISSN
- 0009-9104
- DOI
- 10.1111/j.1365-2249.2010.04268.x
- language
- English
- LU publication?
- yes
- id
- 163958b9-0d5e-486f-8a58-2da97227028e (old id 1732139)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/21062269?dopt=Abstract
- date added to LUP
- 2016-04-04 08:55:07
- date last changed
- 2022-02-06 00:48:08
@article{163958b9-0d5e-486f-8a58-2da97227028e,
abstract = {{Persistent infection with oncogenic human papillomavirus (HPV) is a necessary causal factor in the development of cervical cancer. Moreover, HPV, predominately type 16 and to a lesser degree type 18, is linked causally to varying proportions of other anogenital cancers (vulva, vagina, penis, anus) as well as cancers elsewhere in the body (oropharynx, larynx, conjunctiva). HPV types 6 and 11 cause most of genital warts and recurrent respiratory papillomatosis. Effective prophylactic vaccines have been developed. In this review, we address briefly the immunological aspects of HPV infection and the results of HPV vaccination trials. Internationally standardized monitoring and evaluation of prophylactic HPV vaccination programmes will be essential for arriving at the most cost-effective strategies for cancer control.}},
author = {{Dillner, Joakim and Arbyn, M and Unger, E and Dillner, Lena}},
issn = {{0009-9104}},
language = {{eng}},
pages = {{17--25}},
publisher = {{British Society for Immunology}},
series = {{Clinical and Experimental Immunology}},
title = {{Monitoring of human papillomavirus vaccination.}},
url = {{http://dx.doi.org/10.1111/j.1365-2249.2010.04268.x}},
doi = {{10.1111/j.1365-2249.2010.04268.x}},
volume = {{Dec}},
year = {{2011}},
}